Vaxcyte, Inc.
NasdaqGS:PCVX 株式レポート
Vaxcyte マネジメント 主要情報 CEO給与比率 5.3% CEO在任期間 11yrs CEOの所有権 0.5% 経営陣の平均在職期間 4.5yrs 取締役会の平均在任期間 5.5yrs
経営陣の近況
Co-Founder notifies of intention to sell stock Nov 04
Insufficient new directors Nov 01
President & CFO notifies of intention to sell stock Oct 20
Co-Founder notifies of intention to sell stock Oct 03
Executive VP & COO notifies of intention to sell stock Sep 18
Executive VP & COO notifies of intention to sell stock Sep 05
すべての更新を表示
Co-Founder notifies of intention to sell stock Nov 04
Insufficient new directors Nov 01
President & CFO notifies of intention to sell stock Oct 20
Co-Founder notifies of intention to sell stock Oct 03
Executive VP & COO notifies of intention to sell stock Sep 18
Vaxcyte: Stunning PCV Data Readout Suggests Vaccine Maker Is A Strong Buy Sep 06 Vaxcyte, Inc. has completed a Follow-on Equity Offering in the amount of $1.299998 billion. Sep 06
Executive VP & COO notifies of intention to sell stock Sep 05 Vaxcyte, Inc. has filed a Follow-on Equity Offering. Sep 04
New major risk - Revenue and earnings growth Sep 03
Price target increased by 27% to US$131 Sep 03
Vaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older Sep 03
We're Not Very Worried About Vaxcyte's (NASDAQ:PCVX) Cash Burn Rate Aug 24
President & CFO notifies of intention to sell stock Aug 21
President & CFO notifies of intention to sell stock Jul 21
Vaxcyte Appoints John Furey to Board of Directors Jul 02
President & CFO notifies of intention to sell stock Jun 20
Independent Director notifies of intention to sell stock Jun 06
President & CFO notifies of intention to sell stock May 22
New major risk - Revenue and earnings growth May 10
Vaxcyte (NASDAQ:PCVX) Has Debt But No Earnings; Should You Worry? May 10
President & CFO notifies of intention to sell stock Apr 22
Vaxcyte, Inc., Annual General Meeting, Jun 06, 2024 Apr 16
President & CFO notifies of intention to sell stock Mar 20
New major risk - Revenue and earnings growth Mar 12
Vaxcyte, Inc. Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants Mar 05
New major risk - Revenue and earnings growth Feb 23
President & CFO notifies of intention to sell stock Feb 22
Vaxcyte, Inc. to Report Q4, 2023 Results on Feb 27, 2024 Feb 16 Vaxcyte, Inc. has completed a Follow-on Equity Offering in the amount of $749.999219 million. Vaxcyte, Inc. has completed a Follow-on Equity Offering in the amount of $749.999219 million.
President & CFO notifies of intention to sell stock Jan 21
Vaxcyte, Inc. Appoints Whitney Jones as Chief People Officer Jan 17
Price target increased by 7.8% to US$71.14 Jan 06
Vaxcyte, Inc. Provides Clinical and Regulatory Progress Update on Potential Best-In-Class Pneumococcal Conjugate Vaccine Franchise Jan 05
Co-Founder notifies of intention to sell stock Dec 29
Vaxcyte (NASDAQ:PCVX) Is In A Good Position To Deliver On Growth Plans Dec 27
Senior VP notifies of intention to sell stock Dec 10
Vaxcyte, Inc. Announces the Publication of the Results from the VAX-24 Phase 1/2 Clinical Proof-Of-Concept Study in the Journal The Lancet Infectious Diseases Dec 05
Vaxcyte, Inc. Appoints Jacks Lee to Board of Directors Nov 29
President & CFO notifies of intention to sell stock Nov 24
Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating Vax-31 for the Prevention of Invasive Pneumococcal Disease in Adults Nov 10
President & CFO notifies of intention to sell stock Oct 21
Vaxcyte, Inc. Announces FDA Clearance of Investigational New Drug Application for Vax-31 for the Prevention of Invasive Pneumococcal Disease in Adults Oct 20
Co-Founder notifies of intention to sell stock Sep 27
We're Hopeful That Vaxcyte (NASDAQ:PCVX) Will Use Its Cash Wisely Sep 12
Here's Why We're Not Too Worried About Vaxcyte's (NASDAQ:PCVX) Cash Burn Situation May 30
Vaxcyte, Inc. to Report Q4, 2022 Results on Feb 27, 2023 Feb 17
President exercised options to buy US$1.1m worth of stock. Jan 08
Vaxcyte’S VAX-24 Granted FDA Breakthrough Therapy Designation for the Prevention of Invasive Pneumococcal Disease in Adults Jan 06
Executive VP & COO exercised options to buy US$5.1m worth of stock. Dec 30
We Think Vaxcyte (NASDAQ:PCVX) Can Afford To Drive Business Growth Dec 22
Vaxcyte, Inc. Announces Executive Changes, Effective January 1, 2023 Dec 13
Independent Director exercised options and sold US$131k worth of stock Nov 16
High number of new directors Nov 16
Price target increased to US$60.50 Nov 12
Independent Director exercised options and sold US$147k worth of stock Oct 28
Price target increased to US$56.00 Oct 27
Vaxcyte, Inc. Reports Positive Topline Data from Phase 1/2 Proof-of-Concept Study of its 24 Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Pneumococcal Disease in Adults Aged 18-64 Oct 25
Co-Founder & VP of Research notifies of intention to sell stock Oct 15
Vaxcyte, Inc. Announces Executive Appointments Oct 12
Vaxcyte appoints new CBO, CMO Oct 11
Co-Founder notifies of intention to sell stock Sep 19
Co-Founder & VP of Research notifies of intention to sell stock Sep 10
Vaxcyte, Inc. Completes Enrollment of Phase 2 Study Evaluating Safety, Tolerability and Immunogenicity of VAX-24 in Adults 65 Years and Older Sep 07
Co-Founder notifies of intention to sell stock Aug 19
Co-Founder & VP of Research notifies of intention to sell stock Aug 08
Vaxcyte, Inc. Provides Positive Regulatory Updates for VAX-24 Adult and Pediatric Programs Aug 06
Vaxcyte, Inc. Provides Positive Regulatory Updates for VAX-24 Adult and Pediatric Programs Aug 05
Vaxcyte (NASDAQ:PCVX) Is In A Good Position To Deliver On Growth Plans Aug 05
Insider notifies of intention to sell stock Jul 31
Co-Founder notifies of intention to sell stock Jul 21
President & CFO notifies of intention to sell stock Jul 14
Vaxcyte, Inc. Completes Enrollment of Phase 2 Portion of Phase 1/2 Clinical Proof-Of-Concept Study Evaluating Safety, Tolerability and Immunogenicity of Vax-24 in Adults Jul 13
Vaxcyte completes enrollment in phase 2 portion of study of pneumonia vaccine candidate Jul 12
Executive VP & COO notifies of intention to sell stock Jul 08
Co-Founder notifies of intention to sell stock Jun 25
Co-Founder notifies of intention to sell stock May 20
Co-Founder & VP of Research notifies of intention to sell stock May 09
Insider notifies of intention to sell stock Apr 28
Co-Founder notifies of intention to sell stock Apr 27
High number of new directors Apr 27
Co-Founder notifies of intention to sell stock Apr 22
Vaxcyte, Inc., Annual General Meeting, Jun 01, 2022 Apr 21
Co-Founder & VP of Research notifies of intention to sell stock Apr 09
Vaxcyte, Inc. Announces Doses First Participants in Phase 2 Portion of Ongoing VAX-24 Phase 1/2 Clinical Proof-Of-Concept Study in Adults Apr 06
President & CFO notifies of intention to sell stock Mar 24
Insider notifies of intention to sell stock Mar 15
Chief Operating Officer notifies of intention to sell stock Mar 01
Vaxcyte (NASDAQ:PCVX) Is In A Good Position To Deliver On Growth Plans Feb 25
CEO報酬分析 Vaxcyte の収益と比較して、Grant Pickering の報酬はどのように変化したか？ 日付 総報酬 給与 会社業績 Sep 30 2024 n/a n/a -US$508m
Jun 30 2024 n/a n/a -US$497m
Mar 31 2024 n/a n/a -US$437m
Dec 31 2023 US$12m US$640k -US$402m
Sep 30 2023 n/a n/a -US$300m
Jun 30 2023 n/a n/a -US$265m
Mar 31 2023 n/a n/a -US$245m
Dec 31 2022 US$14m US$601k -US$223m
Sep 30 2022 n/a n/a -US$174m
Jun 30 2022 n/a n/a -US$143m
Mar 31 2022 n/a n/a -US$118m
Dec 31 2021 US$5m US$575k -US$100m
Sep 30 2021 n/a n/a -US$92m
Jun 30 2021 n/a n/a -US$87m
Mar 31 2021 n/a n/a -US$83m
Dec 31 2020 US$3m US$481k -US$89m
Sep 30 2020 n/a n/a -US$83m
Jun 30 2020 n/a n/a -US$73m
Mar 31 2020 n/a n/a -US$64m
Dec 31 2019 US$596k US$426k -US$50m
報酬と市場: Grantの 総報酬 ($USD 12.14M ) は、 US市場 ($USD 12.73M ) の同様の規模の企業の平均とほぼ同じです。
報酬と収益: Grantの報酬は、過去 1 年間の会社の業績と一致しています。
CEO（最高経営責任者 Mr. Grant E. Pickering, M.B.A., is Co-Founder of Vaxcyte, Inc. since 2013 and has been its Chief Executive Officer and Director since November 2013 and served as its President since November 2013 until Dec ... Show more
リーダーシップ・チーム 名称 ポジション 在職期間 報酬 所有権 Co-Founder 11yrs US$12.14m 0.53% $ 68.6m President & CFO 4.5yrs US$5.42m 0.059% $ 7.7m Executive VP & COO 4.9yrs US$5.40m 0.14% $ 17.9m Senior VP 2.6yrs US$3.49m 0.0081% $ 1.0m Co-Founder 11.8yrs データなし データなし Co-Founder & VP of Research no data データなし データなし Senior VP of Finance & Principal Accounting Officer 1.8yrs データなし 0.0031% $ 404.3k Senior Vice President of Corporate Communications & Investor Relations no data データなし データなし Chief People Officer less than a year データなし データなし Senior Vice President of Process Development & Manufacturing 8.6yrs US$2.35m データなし Senior Vice President of Commercial Manufacturing & Supply Chain 3yrs US$1.84m データなし Senior Vice President of Project Management no data データなし データなし
もっと見る
経験豊富な経営陣: PCVXの経営陣は 経験豊富 であると考えられます ( 4.5年の平均在職年数)。
取締役 名称 ポジション 在職期間 報酬 所有権 Co-Founder 11yrs US$12.14m 0.53% $ 68.6m Independent Director 3.2yrs US$704.22k 0.0045% $ 582.6k Independent Director 8.2yrs US$696.72k 0.010% $ 1.3m Independent Director 6.5yrs US$691.72k 0.0045% $ 582.6k Independent Director 4.6yrs US$704.22k 0.0045% $ 582.6k Member of Scientific Advisory Board no data データなし データなし Independent Chairman of the Board 3.1yrs US$724.22k 0.0045% $ 582.6k Member of Scientific Advisory Board no data データなし データなし Member of Scientific Advisory Board 7.8yrs データなし データなし Independent Director 3.2yrs US$704.22k 0.0045% $ 582.6k Member of Scientific Advisory Board no data データなし データなし Member of Scientific Advisory Board no data データなし データなし
もっと見る
経験豊富なボード: PCVXの 取締役会 は 経験豊富 であると考えられます ( 5.5年の平均在任期間)。
Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
